Closing out March and starting April with a few events:

BIO-Europe Spring March 25-27, 2019; Vienna, Austria (Resverlogix and Zenith both listed as presenting companies). Resverlogix at 10:15 AM on Tuesday March 26 and Zenith at 11AM on Wednesday March 27. Local time, so wee hours of the pre-market morning here in US/Canada.

14th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2019): March 26-31, 2019; Lisbon, Portugal (Resverlogix on schedule with 2 abstract, see abstracts here). Great timing with Biogen/Eisai shuttering their aducanumab trial.

American Association for Cancer Research (AACR) March 29 to April 3, 2019. Zenith presenting a poster (see here) on Monday April 1. Hopefully a well received ZEN-3694/mCRPC trial presentation. Shouldn't be long until the ZEN-3694/TNBC trial with Pfizer's PARP inhibitor kicks off. 

BearDownAZ